ATAI
ATAI Life Sciences BV
NASDAQ: ATAI · HEALTHCARE · BIOTECHNOLOGY
$4.12
-4.85% today
Updated 2026-04-29
Market cap
$1.51B
P/E ratio
—
P/S ratio
369.70x
EPS (TTM)
$-2.91
Dividend yield
—
52W range
$1 – $7
Volume
6.2M
WallStSmart proprietary scores
25
out of 100
Grade: F
Strong Sell
Investment rating
7.3
Growth
B+5.0
Quality
C+2.5
Profitability
F6.7
Valuation
B—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →204 stocks currently score above 75
Price targets
Analyst target
$13.92
+237.86%
12-Month target
—
—
Intrinsic (DCF)
$7.66
Margin of safety
+48.17%
2 Strong Buy12 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Revenue growth 1,773.00% QoQ
+ 48.17% below intrinsic value
Risks
- Thin margins at 0.00%
- Negative free cash flow $-48.25M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $233000.00 | $314000.00 | $308000.00 | $4.09M | $4.09M |
| Net income | $-152.38M | $-40.22M | $-149.27M | $-660.05M | $-544.81M |
| EPS | — | — | — | — | $-2.91 |
| Free cash flow | $-105.49M | $-84.71M | $-82.53M | $-103.58M | $-48.25M |
| Profit margin | -65,401.29% | -12,810.19% | -48,463.96% | -16,142.02% | — |
Peer comparison
Smart narrative
ATAI Life Sciences BV trades at $4.12. Our Smart Value Score of 25/100 indicates the stock is weak. TTM revenue stands at $4.09M. Our DCF model estimates intrinsic value at $7.66.
Frequently asked questions
What is ATAI Life Sciences BV's stock price?
ATAI Life Sciences BV (ATAI) trades at $4.12.
Is ATAI Life Sciences BV overvalued?
Smart Value Score 25/100 (Grade F, Strong Sell). DCF value $7.66.
What is the price target of ATAI Life Sciences BV (ATAI)?
The analyst target price is $13.92, representing +237.9% upside from the current price of $4.12.
What is the intrinsic value of ATAI Life Sciences BV (ATAI)?
Based on our DCF model, intrinsic value is $7.66, a +48.2% margin of safety versus $4.12.
What is ATAI Life Sciences BV's revenue?
TTM revenue is $4.09M.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio369.70x
ROE-390.00%
Beta1.57
50D MA$3.88
200D MA$4.25
Shares out0.37B
Float0.30B
Short ratio—
Avg volume6.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—